Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis

IDrugs

Volumn 13, Issue 8, 2010, Pages 568-580

  Martin, L J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CAMPTOTHECIN; GABAPENTIN; MORPHINE; NEUROPROTECTIVE AGENT; OLESOXIME; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; RILUZOLE; TRO 19622; UNCLASSIFIED DRUG; VINCRISTINE;

ADD ON THERAPY; ALLODYNIA; AMYOTROPHIC LATERAL SCLEROSIS; ANTINOCICEPTION; ASTHENIA; BACKACHE; CELL CULTURE; CELL DEATH; CELL REGENERATION; CELL SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CYTOSOL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; HEADACHE; HUMAN; HUNTINGTON CHOREA; HYPERALGESIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MITOCHONDRION; MOLECULAR WEIGHT; MOTOR NERVE; MUSCLE ATROPHY; MUSCLE SPASM; MYELINATION; NERVE CELL; NEUROMUSCULAR FUNCTION; NEUROPROTECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PHARYNGITIS; REVIEW; SINGLE DRUG DOSE; SURVIVAL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CHOLESTENONES; HUMANS; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; NEUROPROTECTIVE AGENTS;

EID: 77955358107     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. 318913 Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH ANN NEUROL 1997 42 4 644-654
2. 356003 Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism. Martin LJ J NEUROPATHOL EXP NEUROL 1999 58 5 459-471
3. 400332 An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL NEURON 1995 14 6 1105-1116
4. 478890 Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW ANN NEUROL 1995 38 1 73-84
5. 478891 Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. Rothstein JD, Martin LJ, Kuncl RW N ENGL J MED 1992 326 22 1464-1468
6. 619434 Trophos initiates phase 1 clinical trial with TRO19622. Trophos PRESS RELEASE 2004 December 15
7. 619475 Trophos and TRO-19622: FAQs. Trophos SA COMPANY PUBLICATION 2005 January 31
8. 638230 Oxidatively modified proteins in aging and disease. Beal MF FREE RADIC BIOL MED 2002 32 9 797-803
9. 647918 Trophos successfully completes phase 1 clinical trials for novel compound to treatment neurodegenerative diseases. Trophos SA PRESS RELEASE 2006 January 31
10. 688521 Trophos granted orphan drug status for TRO19622 for the treatment of amyotrophic lateral sclerosis in Europe. Trophos SA PRESS RELEASE 2006 September 05
11. 732843 TRO19622 is antinociceptive and improves nerve conduction in diabetic rats. Pruss RM, Buisson B, Abitbol J, Marchand F, Malcangio M, Bordet T ABSTR SOC NEUROSCI 2006 36th Atlanta Abs 644.17/T2
12. 795507 Trophos starts phase II clinical trial of TRO19622 in painful diabetic neuropathy. Trophos SA PRESS RELEASE 2007 May 16
13. 806418 Identification and characterization of cholest-4-en-3- one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P, Akentieva NP, Evers AS, Covey DF, Ostuni MA, Lacapere JJ et al J PHARMACOL EXP THER 2007 322 2 709-720
14. 835157 Trophos starts phase Ib clinical trial of TRO19622 in spinal muscular atrophy. Trophos SA PRESS RELEASE 2007 September 28
15. 846908 TRO19622 is well tolerated and achieves target plasma concentrations in a Phase Ib study in ALS patients. Abitbol J-L, Verschueren A, LaComblez L, Cuvier V, Jouve E, Pruss RM, Blin O, Meininger V, Pouget J SOC NEUROSCI ANN MEET 2007 37th November 03 11.10
16. 875224 Trophos SA receives grant from The Michael J. Fox Foundation to evaluate compounds in Parkinson's disease model. Trophos SA PRESS RELEASE 2008 February 08
17. 910845 Trophos demonstrates analgesic activity of neuroprotective agent TRO19622 in preclinical models of painful peripheral neuropathy. Trophos SA PRESS RELEASE 2008 May 29
18. 911450 Specific antinociceptive activity of cholest-4-en-3- one,oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. Bordet T, Buisson B, Michaud M, Abitbol J-L, Marchand F, Grist J, Andriambeloson E, Malcangio M, Pruss RM J PHARMACOL EXP THER 2008 326 2 623-632
19. 972068 Trophos increases focus on neuroprotection and cardioprotection. Trophos SA PRESS RELEASE 2008 December 18
20. 972070 EUR 7 million grants boost Trophos cholesterol-oxime programs for ALS, MS and other neurodegenerative diseases. Trophos SA PRESS RELEASE 2008 December 18
21. 997562 TRO19622, a mitochondrial targeted neuroprotective compound, prevents and reverses paclitaxel-induced painful peripheral neuropathy. Pruss RM, Bordet T, Xiao WH, Bennett GJ NEUROLOGY 2009 72 11 Suppl 3 A211
22. 997568 Safety and pharmacokinetics (PK) of TRO19622 in spinal muscular atrophy (SMA) children and adults. Estournet B, Chabrol B, Cuisset JM, Cances C, Wourgaft NS, Cuvier V, Bassissi F, Bordet T, Pruss R, Abitbol JL NEUROLOGY 2009 72 11 Suppl 3 A276
23. 998571 NCT00876538: Effect of TRO-19622 in the treatment of patients with chemotherapy induced peripheral neuropathy (CIPN). Trophos CLINICALTRIALS.GOV 2009
24. 1006137 Trophos initiates pivotal efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease). Trophos SA PRESS RELEASE 2009 May 05
25. 1040609 Microtubule dynamics modulation in chemotherapyinduced neurotoxicity: A protective role of olesoxime. Rovini A, Carre M, Bordet T, McKay N, Pruss R, Braguer D FEBS J 2009 276 188-189
26. 1040613 TRO19622 is well tolerated and target plasma concentrations are obtained at doses 250/500 mg once a day in a one month ALS phase 1B, add-on to riluzole, clinical study. Verschueren A, Lacomblez L, Abitbol J-L, Cuvier V, Jouve E, Blin O, Meininger V, Pouget J AMYOTROPHIC LATERAL SCLER 2007 8 Suppl 1 Abs C78
27. 1040616 TRO19622 protects cortical neurons from camptothecininduced cell death. Bordet T, Biscarrat C, Giraudon-Paoli M, Pruss RM SOC NEUROSCI ANN MEET 2007 37th Abs 897.16
28. 1043541 Safety and pharmacokinetics of repeated doses of TRO19622, a drug candidate for the treatment of amyotrophic lateral sclerosis and spinal muscular atrophy. Abitbol JL, Cuvier V, Bordet T, Drouot C, Berna P, Pruss RM AMYOTROPHIC LATERAL SCLER 2006 7 Suppl 1 Abs P76
29. 1043542 TRO19622 targets mitochondria and reverses pain in animal models of neuropathic pain. Pruss RM, Buisson B, Cuvier V, Abitbol J-L, Marchand F, Grist J, Malcangio M, Bordet T INT CONGRESS NEUROPATHIC PAIN 2007 2 June 7-10 Abs 163
30. 1057796 Calcium-induced generation of reactive oxygen species in brain mitochondria is mediated by permeability transition. Hansson MJ, Mansson R, Morota S, Uchino H, Kallur T, Sumi T, Ishii N, Shimazu M, Keep MF, Jegorov A, Elmer E FREE RADIC BIOL MED 2008 45 3 284-294
31. 1058089 Evaluation of putative inhibitors of mitochondrial permeability transition for brain disorders-specificity vs. toxicity. Morota S, Mansson R, Hansson MJ, Kasuya K, Shimazu M, Hasegawa E, Yanagi S, Omi A, Uchino H, Elmer E EXP NEUROL 2009 218 2 353-362
32. 1064900 Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Xiao WH, Zheng FY, Bennett GJ, Bordet T, Pruss RM PAIN 2009 147 1-3 202-209
33. 1071528 Clinical trials in CNS - SMi's eighth annual conference. Kirk R IDRUGS 2010 13 2 66-69
34. 1082374 Olesoxime (TRO19622) promotes myelination by induced maturation of oligodendrocyte progenitor cells. Bordet T, Magalon K, Tardif G, Pruss RM, Durbec P GLIA 2009 57 13 S162
35. 1093231 About ALS: Who gets ALS? ALS Assocation INTERNET SITE 2008 September 30
36. 1093240 Medical progress: Amyotrophic lateral sclerosis. Rowland LP, Shneider NA N ENGL J MED 2001 344 22 1688-1700
37. 1093244 Current and emerging treatments for amyotrophic lateral sclerosis. Zoccolella S, Santamato A, Lamberti P NEUROPSYCHIATRIC DIS TREATMENT 2009 5 577-595
38. 1093245 Widespread loss of neuronal populations in the spinal ventral horn in sporadic motor neuron disease. A morphometric study. Stephens B, Guiloff RJ, Navarrete R, Newman P, Nikhar N, Lewis P J NEUROL SCI 2006 244 1-2 41-58
39. 1093247 Cortical selective vulnerability in motor neuron disease: A morphometric study. Maekawa S, Al-Sarraj S, Kibble M, Landau S, Parnavelas J, Cotter D, Everall I, Leigh PN BRAIN 2004 127 1237-1251
40. 1093248 TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Velde CV, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF et al NAT GENET 2008 40 5 572-574
41. 1093249 Genetics of sporadic amyotrophic lateral sclerosis. Schymick JC, Talbot K, Traynor BJ HUM MOL GENET 2007 16 R233-R242
42. 1093281 The mitochondrial permeability transition pore: A molecular target for amyotrophic lateral sclerosis therapy. Martin LJ BIOCHIM BIOPHYS ACTA MOL BASIS DIS 2010 1802 1 186-197
43. 1093283 Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. Martin LJ, Chen K, Liu ZP J NEUROSCI 2005 25 27 6449-6459
44. 1093284 The mitochondrion as Janus Bifrons. Zorov DB, Isaev NK, Plotnikov EY, Zorova LD, Stelmashook EV, Vasileva AK, Arkhangelskaya AA, Khrjapenkova TG BIOCHEMISTRY (MOSCOW) 2007 72 10 1115-1126
45. 1093292 Mitochondrial function and dysfunction in the cell: Its relevance to aging and aging-related disease. Nicholls DG INT J BIOCHEM CELL BIOL 2002 34 11 1372-1381
46. 1093294 Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH, Beal MF J NEUROCHEM 1998 71 1 281-287 (Pubitemid 28292560)
47. 1093295 Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM ANN NEUROL 1999 46 5 787-790
48. 1093300 Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Vielhaber S, Kunz D, Winkler K, Wiedemann FR, Kirches E, Feistner H, Heinze HJ, Elger CE, Schubert W, Kunz WS BRAIN 2000 123 1339-1348
49. 1093303 Activities of mitochondrial complexes correlate with nNOS amount in muscle from ALS patients. Soraru G, Vergani L, Fedrizzi L, D'Ascenzo C, Polo A, Bernazzi B, Angelini C NEUROPATHOL APPL NEUROBIOL 2007 33 2 204-211
50. 1093307 Single-cell analysis of mtDNA levels in sporadic amyotrophic lateral sclerosis. Mawrin C, Kirches E, Krause G, Wiedemann FR, Vorwerk CK, Bogerts B, Schildhaus HU, Dietzmann K, Schneider-Stock R NEUROREPORT 2004 15 6 939-943
51. 1093310 Ultrastructural changes of synapses of Betz cells in patients with amyotrophic lateral sclerosis. Sasaki S, Iwata M NEUROSCI LETT 1999 268 1 29-32
52. 1093324 Mitochondrial involvement in amyotrophic lateral sclerosis. Menzies FM, Ince PG, Shaw PJ NEUROCHEM INT 2002 40 6 543-551
53. 1093325 Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: A temporal study in man. Echaniz-Laguna A, Zoll J, Ponsot E, N'Guessan B, Tranchant C, Loeffler JP, Larnpert E EXP NEUROL 2006 198 1 25-30
54. 1093328 Visualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosis. Vielhaber S, Winkler K, Kirches E, Kunz D, Buchner M, Feistner H, Elger CE, Ludolph AC, Riepe MW, Kunz WS J NEUROL SCI 1999 169 1-2 133-139
55. 1093329 Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Siklos L, Engelhardt J, Harati Y, Smith RG, Joo F, Appel SH ANN NEUROL 1996 39 2 203-216
56. 1093331 Neurodegeneration - cellular defences destroyed. Choi DW NATURE 2005 433 7027 696-698
57. 1093335 Glutamatergic neurotransmission in Alzheimer's disease. Cowburn RF, Hardey JA, Roberts PJ BIOCHEM SOC TRANS 1990 18 3 390-392
58. 1093336 Fimbria-fornix transections selectively down-regulate subtypes of glutamate transporter and glutamate receptor proteins in septum and hippocampus. Ginsberg SD, Rothstein JD, Price DL, Martin LJ J NEUROCHEM 1996 67 3 1208-1216
59. 1093337 Quantitative assessment of AMPA receptor mRNA in human spinal motor neurons isolated by laser capture microdissection. Heath PR, Tomkins J, Ince PG, Shaw PJ NEUROREPORT 2002 13 14 1753-1757
60. 1093351 Deficient RNA editing of GluR2 and neuronal death in amyotrophic lateral sclerosis. Kwak S, Kawahara Y J MOL MED 2005 83 2 110-120 (Pubitemid 40379299)
61. 1093353 Mitochondrial trafficking and morphology in healthy and injured neurons. Chang DTW, Reynolds IJ PROG NEUROBIOL 2006 80 5 241-268
62. 1093355 Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH, Beal MF J NEUROCHEM 1997 69 5 2064-2074
63. 1093357 Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Abe K, Pan LH, Watanabe M, Kato T, Itoyama Y NEUROSCI LETT 1995 199 2 152-154
64. 1093360 iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Sasaki S, Shibata N, Komori T, Iwata M NEUROSCI LETT 2000 291 1 44-48
65. 1093696 Impact of mitochondrial inhibition on excitability and cytosolic ca2+ levels in brainstern motoneurones from mouse. Bergmann F, Keller BU J PHYSIOL LONDON 2004 555 1 45-59
66. 1093997 Opportunities for neuroprotection in ALS using cell death mechanism rationales. Martin LJ, Liu Z DRUG DISC TODAY 2004 1 2 135-143
67. 1093998 Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis. Martin LJ, Al-Abdulla NA, Brambrink AM, Kirsch JR, Sieber FE, Portera-Cailliau C BRAIN RES BULL 1998 46 4 281-309
68. 1094007 Neuronal cell death in nervous system development, disease, and injury (review). Martin LJ INT J MOL MED 2001 7 5 455-478
69. 1094022 p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Martin LJ NEUROBIOL DIS 2000 7 6 613-622
70. 1094031 Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer D, Schuler M, Green DR SCIENCE 2004 303 5660 1010-1014
71. 1094033 Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Ferri A, Cozzolino M, Crosio C, Nencini M, Casciati A, Gralla EB, Rotilio G, Valentine JS, Carri MT PROC NATL ACAD SCI USA 2006 103 37 13860-13865
72. 1094034 Low levels of ALS-linked Cu/Zn superoxide dismutase increase the production of reactive oxygen species and cause mitochondrial damage and death in motor neuron-like cells. Rizzardini M, Mangolini A, Lupi M, Ubezio P, Bendotti C, Cantoni L J NEUROL SCI 2005 232 1-2 95-103
73. 1094036 Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. Flanagan SW, Anderson RD, Ross MA, Oberley LW J NEUROCHEM 2002 81 1 170-177
74. 1094037 Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. Bendotti C, Calvaresi N, Chiveri L, Prelle A, Moggio M, Braga M, Silani V, De Biasi S J NEUROL SCI 2001 191 1-2 25-33
75. 1094039 Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. Kong JM, Xu ZS J NEUROSCI 1998 18 9 3241-3250
76. 1094040 CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Jaarsma D, Rognoni F, van Duijn W, Verspaget HW, Haasdijk ED, Holstege JC ACTA NEUROPATHOL 2001 102 4 293-305
77. 1094042 Mutant Cu, Zn Superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. Higgins CMJ, Jung CW, Ding HL, Xu ZS J NEUROSCI 2002 22 6 1-6
78. 1094044 ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. Higgins CMJ, Jung CW, Xu ZS BMC NEUROSCI 2003 4
79. 1094045 Ultrastructural study of mitochondria in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Sasaki S, Warita H, Murakami T, Abe K, Iwata M ACTA NEUROPATHOL 2004 107 5 461-474 (Pubitemid 38559256)
80. 1094046 Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: Mechanisms of mitochondriopathy and cell death. Martin LJ, Liu ZP, Chen K, Price AC, Pan Y, Swaby JA, Golden WC J COMP NEUROL 2007 500 1 20-46
81. 1094047 Glycinergic innervation of motoneurons is deficient in amyotrophic lateral sclerosis mice: A confocal quantitative analysis. Chang Q, Martin LJ AM J PATHOL 2009 174 2 574-585
82. 1094048 The mitochondrial permeability transition pore in motor neurons: Involvement in the pathobiology of ALS mice. Martin LJ, Gertz B, Pan Y, Price AC, Molkentin JD, Chang Q EXP NEUROL 2009 218 2 333-346
83. 1094065 Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, Getzoff ED, Hu P, Herzfeldt B, Roos RP, Warner C et al SCIENCE 1993 261 5124 1047-1051
84. 1094089 Superoxide-dismutase-1 with mutations linked to familial amyotrophic-lateral-sclerosis possesses significant activity. Borchelt DR, Lee MK, Slunt HS, Guarnieri M, Xu ZS, Wong PC, Brown RH, Price DL, Sisodia SS, Cleveland DW PROC NATL ACAD SCI USA 1994 91 17 8292-8296
85. 1094092 A gain-of-function of an amyotrophic lateral sclerosisassociated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Yim MB, Kang JH, Yim HS, Kwak HS, Chock PB, Stadtman ER PROC NATL ACAD SCI USA 1996 93 12 5709-5714
86. 1094097 Oxidized/misfolded superoxide dismutase-1: The cause of all amyotrophic lateral sclerosis? Kabashi E, Valdmanis PN, Dion P, Rouleau GA ANN NEUROL 2007 62 6 553-559
87. 1094099 Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. Abou Ezzi S, Urushitani M, Julien JP J NEUROCHEM 2007 102 1 170-178
88. 1094141 ALS, SOD and peroxynitrite. Beckman JS, Carson M, Smith CD, Koppenol WH NATURE 1993 364 6438 584-584
89. 1094388 Mutant Cu,Zn superoxide dismutases and familial amyotrophic lateral sclerosis: Evaluation of oxidative hypotheses. Liochev SI, Fridovich I FREE RADIC BIOL MED 2003 34 11 1383-1389
90. 1094393 Nitric oxide and peroxynitrite in health and disease. Pacher P, Beckman JS, Liaudet L PHYSIOL REV 2007 87 1 315-424
91. 1094428 Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. Andrus PK, Fleck TJ, Gurney ME, Hall ED J NEUROCHEM 1998 71 5 2041-2048
92. 1094429 Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice- a model of familial amyotrophic lateral sclerosis. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, Klein JB, Calabrese V, Butterfield DA FREE RADIC BIOL MED 2005 39 4 453-462 (Pubitemid 41021644)
93. 1094430 Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. Yan LJ, Sohal RS PROC NATL ACAD SCI USA 1998 95 22 12896-12901
94. 1094431 Mass spectrometry-based survey of age-associated protein carbonylation in rat brain mitochondria. Prokai L, Yan LJ, Vera-Serrano JL, Stevens SM, Forster MJ J MASS SPECTROM 2007 42 12 1583-1589
95. 1094432 The adenine nucleotide translocator: A target of nitric oxide, peroxynitrite, and 4-hydroxynonenal. Vieira HLA, Belzacq AS, Haouzi D, Bernassola F, Cohen I, Jacotot E, Ferri KF, El Hamel C, Bartle LM, Melino G, Brenner C et al ONCOGENE 2001 20 32 4305-4316
96. 1094434 Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. McStay GP, Clarke SJ, Halestrap AP BIOCHEM J 2002 367 541-548
97. 1094435 Lessons from models of SOD1-linked familial ALS. Bendotti C, Carri MT TRENDS MOL MED 2004 10 8 393-400
98. 1094436 Induction of the mitochondrial permeability transition by N-ethylmaleimide depends on secondary oxidation of critical thiol groups. Costantini P, Colonna R, Bernardi P BIOCHIM BIOPHYS ACTA BIOENERG 1998 1365 3 385-392
99. 1094437 Copper induces permeability transition through its interaction with the adenine nucleotide translocase. Garcia N, Martinez-Abundis E, Pavon N, Correa F, Chavez E CELL BIOL INT 2007 31 9 893-899
100. 1094438 Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF, Brownlees J, Ackerley S, Shaw PJ, McLoughlin DM, Shaw CE et al HUM MOL GENET 2007 16 2720-2728
101. 1094439 Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. Martin LJ J NEUROPATHOL EXP NEUROL 2006 65 12 1103-1110
102. 1094440 Deleterious role of superoxide dismutase in the mitochondrial intermembrane space. Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Jaronen M, Arens E, Akerman K, Chan PH, Koistinaho J J BIOL CHEM 2008 283 13 8446-8452
103. 1094441 Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. Vijayvergiya C, Beal MF, Buck J, Manfredi G J NEUROSCI 2005 25 10 2463-2470
104. 1094442 Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. Mattiazzi M, D'Aurelio M, Gajewski CD, Martushova K, Kiaei M, Beal MF, Manfredi G J BIOL CHEM 2002 277 33 29626-29633
105. 1094483 Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Keep M, Elmer E, Fong KSK, Csiszar K BRAIN RES 2001 894 2 327-331
106. 1094492 Life span extension and reduced neuronal death after weekly intraventricular cyclosporine injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. Karlsson J, Fong KSK, Hansson MJ, Elmer E, Csiszar K, Keep MF J NEUROSURG 2004 101 1 128-137
107. 1094493 An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. Kirkinezos IG, Hernandez D, Bradley WG, Moraes CT J NEUROCHEM 2004 88 4 821-826
108. 1094496 Relationship between configuration, function, and permeability in calcium-treated mitochondria. Hunter DR, Haworth RA, Southard JH J BIOL CHEM 1976 251 16 5069-5077
109. 1094497 The mitochondrial permeability transition pore and its role in cell death. Crompton M BIOCHEM J 1999 341 233-249
110. 1094498 Mitochondrial intermembrane proteins in cell death. van Gurp M, Festjens N, van Loo G, Saelens X, Vandenabeele P BIOCHEM BIOPHYS RES COMMUN 2003 304 3 487-497
111. 1094499 The mitochondrial permeability transition from in vitro artifact to disease target. Bernardi P, Krauskopf A, Basso E, Petronilli V, Blalchy-Dyson E, Di Lisa F, Forte MA FEBS J 2006 273 10 2077-2099
112. 1094500 Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Leung AWC, Halestrap AP BIOCHIM BIOPHYS ACTA BIOENERG 2008 1777 7-8 946-952
113. 1094501 The voltage-dependent anion channel (VDAC): Function in intracellular signalling, cell life and cell death. Shoshan- Barmatz V, Israelson A, Brdiczka D, Sheu SS CURR PHARM DESIGN 2006 12 18 2249-2270
114. 1094514 The mitochondrial voltage-dependent anion channel (VDAC) as a therapeutic target for initiating cell death. Granville DJ, Gottlieb RA CURR MED CHEM 2003 10 16 1527-1533
115. 1094515 The adenine nucleotide translocase: A central component of the mitochondrial permeability transition pore and key player in cell death. Halestrap AP, Brenner C CURR MED CHEM 2003 10 16 1507-1525
116. 1094528 Ro5-4864 promotes neonatal motor neuron survival and nerve regeneration in adult rats. Mills C, Makwana M, Wallace A, Benn S, Schmidt H, Tegeder I, Costigan M, Brown RH, Raivich G, Woolf CJ EUR J NEUROSCI 2008 27 4 937-946
117. 1094532 Subcellular localization of VDAC in mitochondria and ER in the cerebellum. Shoshan-Barmatz V, Zalk R, Gincel D, Vardi N BIOCHIM BIOPHYS ACTA BIOENERG 2004 1657 2-3 105-114
118. 1094536 Voltage-dependent anion channels (VDAC) in the plasma membrane play a critical role in apoptosis in differentiated hippocampal neurons but not in neural stem cells. Akanda N, Tofighi R, Brask J, Tamm C, Elinder F, Ceccatelli S CELL CYCLE 2008 7 20 3225-3234
119. 1094537 Subcellular localization of human voltage-dependent anion channel isoforms. Yu WH, Wolfgang W, Forte M J BIOL CHEM 1995 270 23 13998-14006
120. 1094653 Chapter 4: Cell and tissue microdissection in combination with genomic and proteomic applications. Ginsberg SD, Hemby SE, Mufson EJ, Martin LJ NEUROANATOMICAL TRACT-TRACING 3 (EDS: ZABORSZKY L, WOUTERLOOD FG, LANCIEGO JL) 2006 Springer, New York, NY, USA 3rd Edition 109-141
121. 1094927 On the role of VDAC in apoptosis: Fact and fiction. Rostovtseva TK, Tan WZ, Colombini M J BIOENERG BIOMEMBR 2005 37 3 129-142
122. 1107246 Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Boukaftane Y, Khoris J, Moulard B, Salachas F, Meininger V, Malafosse A, Camu W, Rouleau GA CAN J NEUROL SCI 1998 25 3 192-196
123. 1111760 Signal transduction to the permeability transition pore. Rasola A, Sciacovelli M, Pantic B, Bernardi P FEBS LETT 2010 584 10 1989-1996
124. 1111761 Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Wong M, Martin LJ HUM MOL GENET 2010 19 11 2284-2302